Literature DB >> 2570641

The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family.

S Schulz1, S Singh, R A Bellet, G Singh, D J Tubb, H Chin, D L Garbers.   

Abstract

Atrial natriuretic peptide (ANP) binds directly to a plasma membrane form of guanylate cyclase (GC-A), stimulating the production of the second messenger cyclic GMP. We show that a second guanylate cyclase/receptor (GC-B) exists, with distinctly different specificities for various natriuretic peptides. A cDNA clone encoding GC-B was isolated by low-stringency screening of a rat brain cDNA library using GC-A cDNA as a probe. The deduced amino acid sequence of GC-B is 78% identical with GC-A within the intracellular region, but 43% identical within the extracellular domain. Cyclic GMP concentrations in cells transfected with GC-A were half-maximally elevated at 3 nM ANP, 25 nM brain natriuretic peptide (BNP), and 65 nM atriopeptin 1, while 25 microM ANP, 6 microM BNP, and greater than 100 microM atriopeptin 1 were required for half-maximal stimulation of GC-B. The potencies of natriuretic peptides on GC-A and GC-B activity are therefore markedly different; furthermore, despite the specificity of GC-B for BNP, the relatively high BNP concentration required to elicit a response suggests the possible presence of a more potent, unidentified natural ligand.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570641     DOI: 10.1016/0092-8674(89)90513-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  120 in total

1.  Inhibition of atrial natriuretic peptide (ANP) C receptor expression by antisense oligodeoxynucleotides in A10 vascular smooth-muscle cells is associated with attenuation of ANP-C-receptor-mediated inhibition of adenylyl cyclase.

Authors:  A Palaparti; Y Li; M B Anand-Srivastava
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

2.  RNA: a method to specifically inhibit PCR amplification of known members of a multigene family by degenerate primers.

Authors:  P S Yuen; K M Brooks; Y Li
Journal:  Nucleic Acids Res       Date:  2001-03-15       Impact factor: 16.971

Review 3.  The Venus flytrap of periplasmic binding proteins: an ancient protein module present in multiple drug receptors.

Authors:  C B Felder; R C Graul; A Y Lee; H P Merkle; W Sadee
Journal:  AAPS PharmSci       Date:  1999

Review 4.  Natriuretic peptide receptor: structure and signaling.

Authors:  Kunio S Misono
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

Review 5.  Ultracytochemistry as a tool for the study of the cellular and subcellular localization of membrane-bound guanylate cyclase (GC) activity. Applicability to both receptor-activated and receptor-independent GC activity.

Authors:  Maria Grazia Rambotti; Antonio Spreca; Ileana Giambanco; Guglielmo Sorci; Rosario Donato
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

Review 6.  Evolution of the membrane guanylate cyclase transduction system.

Authors:  Rameshwar K Sharma
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

7.  Glycosylation of asparagine 24 of the natriuretic peptide receptor-B is crucial for the formation of a competent ligand binding domain.

Authors:  R Fenrick; N Bouchard; N McNicoll; A De Léan
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

8.  Effects of atrial natriuretic peptide and vasopressin on chloride transport in long- and short-looped medullary thick ascending limbs.

Authors:  H Nonoguchi; K Tomita; F Marumo
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 9.  Receptor guanylyl cyclases.

Authors:  S K Wong; D L Garbers
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

10.  Conservation of the kinaselike regulatory domain is essential for activation of the natriuretic peptide receptor guanylyl cyclases.

Authors:  K J Koller; F J de Sauvage; D G Lowe; D V Goeddel
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.